Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
norephedrine
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Norephedrine is a psychoactive small molecule that acts as an indirect sympathomimetic, primarily by inducing the release of noradrenaline, which leads to increased cardiac contractility and heart rate. It is an amphetamine analogue and a natural constituent of the khat plant (Catha edulis) and Ephedra herba. Norephedrine is also a metabolite of methamphetamine and serves as a pharmaceutical intermediate in the synthesis of other drugs like ephedrine and pseudoephedrine. It has been identified as a critical active ingredient in traditional Chinese medicine (Yangke powder) for alleviating allergic asthma, where it modulates the PI3K/AKT/NF-κB pathway.
- Other names
- (1R, 2S)-(-)-norephedrine(1R, 2S)-norephedrineNE
02
Targets
ADRA1A (α1A)ADRA2A (α2A)ADRB1 (β1)
Beyond the preview
Go deeper on norephedrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on norephedrine.